GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Telix Pharmaceuticals Ltd (OTCPK:TLPPF) » Definitions » Revenue

TLPPF (Telix Pharmaceuticals) Revenue : $507.0 Mil (TTM As of Dec. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Telix Pharmaceuticals Revenue?

Telix Pharmaceuticals's revenue for the six months ended in Dec. 2024 was $268.8 Mil. Its revenue for the trailing twelve months (TTM) ended in Dec. 2024 was $507.0 Mil. Telix Pharmaceuticals's Revenue per Share for the six months ended in Dec. 2024 was $0.77. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2024 was $1.47.

Warning Sign:

Telix Pharmaceuticals Ltd revenue growth has slowed down over the past 12 months.

During the past 12 months, the average Revenue per Share Growth Rate of Telix Pharmaceuticals was 46.20% per year. During the past 3 years, the average Revenue per Share Growth Rate was 411.00% per year. During the past 5 years, the average Revenue per Share Growth Rate was 230.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

During the past 10 years, Telix Pharmaceuticals's highest 3-Year average Revenue per Share Growth Rate was 411.00% per year. The lowest was 157.10% per year. And the median was 283.40% per year.


Telix Pharmaceuticals Revenue Historical Data

The historical data trend for Telix Pharmaceuticals's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Telix Pharmaceuticals Revenue Chart

Telix Pharmaceuticals Annual Data
Trend Sep99 Sep00 Jun17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.52 3.50 108.03 336.38 496.02

Telix Pharmaceuticals Semi-Annual Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 92.84 146.52 190.25 238.20 268.83

Competitive Comparison of Telix Pharmaceuticals's Revenue

For the Biotechnology subindustry, Telix Pharmaceuticals's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Telix Pharmaceuticals's Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Telix Pharmaceuticals's Revenue distribution charts can be found below:

* The bar in red indicates where Telix Pharmaceuticals's Revenue falls into.



Telix Pharmaceuticals Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was $507.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Telix Pharmaceuticals  (OTCPK:TLPPF) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


Telix Pharmaceuticals Revenue Related Terms

Thank you for viewing the detailed overview of Telix Pharmaceuticals's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Telix Pharmaceuticals Business Description

Traded in Other Exchanges
Address
55 Flemington Road, Suite 401, North Melbourne, Melbourne, VIC, AUS, 3051
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.